Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications

Journal of Cardiac Failure

Volumn 14, Issue 5, 2008, Pages 414-419

  Payá, Eduardo ^a   Marín, Francisco ^a,b   González, Josefa ^b   Gimeno, Juan Ramón ^b   Feliu, Eloísa ^a   Romero, Antonio ^b   Ruiz Espejo, Francisco ^b   Roldán, Vanessa ^c   Climent, Vicente ^a   de la Morena, Gonzalo ^b   Valdés, Mariano ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

cardiac magnetic resonance; gadolinium hyperenhancement; Hypertrophic cardiomyopathy; NTproBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGEN; GADOLINIUM;

ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EXERCISE TOLERANCE; FEMALE; FUNCTIONAL STATUS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SIZE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SUDDEN DEATH;

C-REACTIVE PROTEIN; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 44349165836     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.02.006     Document Type: Article

References (37)

1. St John Sutton M.G., Lie J.T., Anderson K.R., O'Brien P.C., and Frye R.L. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J 44 (1980) 433-443
2. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
3. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
4. Tsuruda T., Boerringter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Cir Res 91 (2002) 1127-1134
5. McKenna W.J., Spirito P., Desnos M., Dubourg O., and Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77 (1997) 130-132
6. Fananapazir L., and McAreavey D. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol 20 (1997) 478-501
7. Spirito P., Bellone P., Harris K.M., Bernabó P., Bruzzi P., and Maron B.J. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 324 (2000) 1778-1785
8. Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
9. Sadoul N., Prasad K., Elliott P.M., Bannerjee S., Frenneaux M.P., and McKenna W.J. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96 (1997) 2987-2991
10. Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., Penas-Lado M., and McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42 (2003) 873-879
11. Pohost G.M., Hung L., and Doyle M. Clinical use of cardiovascular magnetic resonance. Circulation 108 (2003) 647-653
12. Kim R.J., Fieno D.S., Parrish T.B., Harris K., Chen E., Simonetti O., et al. Relation of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
13. Moon J.C. What is late gadolinium enhancement in hypertrophic cardiomyopathy?. Rev Esp Cardiol 60 (2007) 1-4
14. Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J 24 (2003) 2151-2155
15. Moon J.C., Sheppard M., Reed E., Lee P., Elliott P.M., and Pennell D.J. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8 (2006) 479-482
16. Bogaert J., Goldstein M., Tannouri F., Golzarian J., and Dymarkowski S. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR Am J Roentgenol 180 (2003) 981-985
17. Wilson J.M., Villareal R.P., Hariharan R., Massumi A., Muthupillai R., and Flamm S.D. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 29 (2002) 176-180
18. Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
19. Teraoka K., Hirano M., Ookubo H., Sasaki K., Katsuyama H., Amino M., et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 22 (2004) 155-161
20. Debl K., Djavidani B., Buchner S., Lipke C., Nitz W., Feuerbach S., et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92 (2006) 1447-1451
21. Pujadas S., Carreras F., Arrastio X., Leta R., Vila M., Subirana M.T., et al. Detection and quantification of myocardial fibrosis in hypertrophic cardiomyopathy by contrast-enhanced cardiovascular magnetic resonance. Rev Esp Cardiol 60 (2007) 10-14
22. Dumont C., Monserrat L., Soler R., Rodríguez E., Fernández X., Peteiro J., et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 60 (2007) 15-23
23. Soler R., Rodríguez E., Monserrat L., Mendez C., and Martínez C. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. J Comput Assist Tomogr 30 (2006) 412-420
24. Hurwitz J.L., and Josephson M.E. Sudden cardiac death in patients with chronic coronary heart disease. Circulation 85 (1992) 143-149
25. Matoh F., Satoh H., Shiraki K., Saitoh T., Urushida T., Katoh H., et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Cardiac Fail 13 (2007) 372-379
26. Thaman R., Esteban M.T., Barnes S., Gimeno J.R., Mist B., Murphy R., et al. Usefulness of N-terminal Pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 515-519
27. Arteaga E., Araujo A.Q., Buck P., Ianni B.M., Rabello R., and Mady C. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150 (2005) 1228-1232
28. Maron B.J., Tholakanahalli V.N., Zenovich A.G., Casey S.A., Duprez D., Aeppli D.M., et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109 (2004) 984-989
29. Pieroni M., Bellocci F., Sanna T., Verardo R., Ierardi C., Masseri A., et al. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Cardiac Fail 13 (2007) 380-388
30. Cochet A., Zeller M., Cottin Y., Robert-Valla C., Lalande A., ĹHuilllier I., et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail 6 (2004) 555-560
31. Paelick B.P., Vrints C.J., Bax J.J., Bosmans J.M., De Hert S.G., de Roos A., et al. Relation of B-type natriuretic peptide early after acute myocardial infarction to left ventricular diastolic function and extent of myocardial damage determined by magnetic resonance imaging. Am J Cardiol 97 (2006) 1146-1150
32. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 (2004) 453-461
33. Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliú E, et al. Matrix metalloproteinases and tissue remodelling in hypertrophic cardiomyopathy. Am Heart J. In press.
34. Haverkate F., Thompson S.G., and Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost 73 (1995) 561-567
35. Gach O., Legrand V., Biessaux Y., Chapelle J.P., Vanbelle S., and Pierard L.A. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 99 (2007) 31-35
36. May H.T., Muhlenstein J.B., Carlquist J.F., Horne B.D., Bair T.L., Campbell B.A., et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 98 (2006) 653-658
37. Siirila-Waris K., Lassus J., Melin J., Peuhkurinen K., Nieminen M.S., and Harjola V.P. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 27 (2006) 3011-3017